Can a patient with Sjögren’s syndrome develop idiopathic intracranial hypertension (IIH)?

Can a Patient with Sjögren's Syndrome Develop IIH?

Yes, patients with Sjögren's syndrome can develop intracranial hypertension, though this is a rare manifestation that requires careful evaluation to distinguish between true idiopathic intracranial hypertension (IIH) and secondary intracranial hypertension related to the autoimmune disease.

Understanding the Association

While the 2018 consensus guidelines on IIH management 1 emphasize that IIH is diagnosed only after excluding secondary causes, documented case reports confirm that Sjögren's syndrome can present with intracranial hypertension. A case report describes intracranial hypertension as the first manifestation of primary Sjögren's syndrome 2, and another recent case documents intracranial hypertension syndrome as an unusual manifestation requiring high-dose corticosteroid treatment 3.

Critical Diagnostic Distinction

The key clinical challenge is determining whether this represents:

• True IIH (coincidental occurrence in a patient who happens to have Sjögren's syndrome)
• Secondary intracranial hypertension (directly caused by the autoimmune process)

When to Suspect Secondary Causes

Patients with Sjögren's syndrome presenting with signs of raised intracranial pressure should be classified as "atypical IIH" and require more in-depth investigation 1. The systematic review on secondary intracranial hypertension emphasizes that even patients with typical IIH phenotype should be screened for secondary causes 4.

Atypical features warranting heightened suspicion include:

• Active systemic autoimmune disease manifestations
• Abnormal CSF findings beyond elevated opening pressure
• Cranial nerve involvement beyond sixth nerve palsy
• Abnormal meningeal enhancement on imaging
• Poor response to standard IIH therapies

Diagnostic Workup Algorithm

Step 1: Confirm Raised Intracranial Pressure

• Urgent MRI brain within 24 hours (CT if MRI unavailable) 1
• MR/CT venography mandatory to exclude cerebral sinus thrombosis 1
• Lumbar puncture with opening pressure measurement in lateral decubitus position 1
• CSF analysis must be normal (no pleocytosis, elevated protein, or infectious organisms) for IIH diagnosis

Step 2: Assess for Secondary Causes

• Evaluate for active Sjögren's disease activity (complement levels, inflammatory markers)
• Screen for other autoimmune conditions (similar to SLE, which can also present with intracranial hypertension 5)
• Review medications that could cause secondary intracranial hypertension 4
• Assess for anemia, renal disease, and hypertension—common comorbidities in secondary intracranial hypertension 4

Step 3: Determine Phenotype Classification

• Typical IIH: Female, childbearing age, BMI >30 kg/m² 1
• Atypical IIH: Does not meet typical criteria OR has underlying autoimmune disease 1

Management Approach

If Classified as Secondary to Sjögren's Syndrome

Treat the underlying autoimmune disease first 3:

• High-dose corticosteroids as initial therapy
• Consider immunosuppressive agents (hydroxychloroquine, mycophenolate) based on systemic disease activity
• Monitor for clinical and imaging response to immunotherapy

If Classified as True IIH (Coincidental)

Follow standard IIH management principles 1:

Primary disease modification:

• Weight loss for BMI >30 kg/m² (only disease-modifying therapy in typical IIH) 1

Vision protection:

• Acetazolamide starting 250-500 mg twice daily, titrating up (maximum 4 g/day) 1
• Urgent surgical intervention (VP shunt preferred over LP shunt) if vision deteriorating 1
• Follow-up intervals based on papilledema grade and visual field status (see Table 4 in guidelines) 1

Headache management:

• Short-term NSAIDs or paracetamol (avoid opioids) 1
• Migraine preventatives for migrainous phenotype (68% of IIH patients) 1
• Address medication overuse early 1

Critical Pitfalls to Avoid

1. Do not assume all intracranial hypertension in Sjögren's patients is "idiopathic"—the autoimmune process may be causative 2, 3

2. Do not delay immunosuppressive therapy if secondary etiology suspected—case reports show favorable response to corticosteroids 3

3. Do not overlook vision monitoring—permanent vision loss can occur regardless of etiology. Follow structured monitoring intervals based on papilledema severity 1

4. Do not perform serial lumbar punctures for management—these are not recommended and provide only temporary relief 1

5. Do not use CSF shunting for headache alone—68% continue having headaches at 6 months, 79% at 2 years 1

Ongoing Monitoring Considerations

Patients with Sjögren's syndrome and intracranial hypertension require:

• Coordinated care between neurology, ophthalmology, and rheumatology
• Regular visual field testing and optical coherence tomography
• Assessment for both disease activity of Sjögren's and ICP control
• Vigilance for recurrence, as patients may be asymptomatic at presentation 1

The association between autoimmune diseases like Sjögren's syndrome and intracranial hypertension, while rare, is well-documented 2, 3, 5. The critical clinical decision is determining whether immunosuppressive therapy targeting the autoimmune disease is warranted versus standard IIH management alone.